Balyasny Asset Management LLC Moon Lake Immunotherapeutics Call Options Transaction History
Balyasny Asset Management LLC
- $72.4 Billion
- Q3 2025
Call Options
1 transactions
Others Institutions Holding MLTX
# of Institutions
165Shares Held
41.7MCall Options Held
2.58MPut Options Held
1.01M-
Bvf Inc San Francisco, CA19.8MShares$252 Million7.66% of portfolio
-
Avoro Capital Advisors LLC New York, NY2MShares$25.5 Million0.2% of portfolio
-
Cormorant Asset Management, LP Boston, MA1.99MShares$25.5 Million2.28% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA1.5MShares$19.2 Million0.02% of portfolio
-
Schonfeld Strategic Advisors LLC New York, NY965KShares$12.3 Million0.05% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $472M
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...